Shirani and coauthors analyzed data from 2656 patients with relapsing-remitting multiple sclerosis in British Columbia from 1985 to 2008 to investigate whether treatment with interferon beta was associated with a reduction in disability progression. In an 8327, Derfuss and Kappos discuss interferon’s potential benefits in MS.
Fonarow and coauthors used data on 127 950 Medicare beneficiaries with acute ischemic stroke to evaluate how hospital outcome ratings are altered after including initial stroke severity in claims-based hospital mortality risk models. In an 8448, Kurth and Elkind discuss the importance of incorporating stroke severity when conducting health outcomes research in stroke.
Dr Landon and coauthors report on variations in patient-sharing networks of physicians across the United States. In an accompanying 7476, Drs Lewis and Fisher discuss social networks in health care.
To determine the effect of silymarin on liver disease activity in patients with chronic hepatitis C virus (HCV) infection unsuccessfully treated with interferon-based therapy, Fried and coauthors randomly assigned 154 such patients to receive 420-mg silymarin, 700-mg silymarin, or matching placebo.
Gordin and Masur discuss the resurgence in developing new tools and approaches in public health infrastructure of tuberculosis in the United States. See the
related 7511 by LoBue and Castro.